Cavallaro Roberto Professore OrdinarioMedicinaMED/25 - Psichiatria

Presidente del Corso di Laurea in Medicina e Chirurgia dell’Università Vita-Salute San Raffaele.

Medico Chirurgo, Psichiatria, è Professore ordinario di Psichiatria presso  La Facoltà di Medicina e Chirurgia dell’Università Vita-Salute San Raffaele. Laureato con Lode Presso l’università degli Studi di Milano nel 1987 e specializzato in Psichiatria con Lode presso L’università degli Studi di Milano nel 1991, ha percorso l’intera carriere clinica, di ricerca e di insegnamento all’Interno dell’ IRCCS Universitario Ospedale San Raffaele e dell’Università Vita-Salute San Raffaele.

Attualmente è  Responsabile di Unità Operativa Complessa  delle Unità di Psichiatria Generale e Riabilitazione Psichiatria Generale e della ‘Disease Unit’ per i disturbi Psicotici presso l’IRCCS Universitario  San Raffaele, sede di Turro.

Dal 2001 è stato docente negli ambiti delle Facoltà di Medicina e Chirurgia e Psicologia dell’Università Vita Salute con Affidamenti e Incarichi  in qualità di Professore a Contratto presso Le Scuole Di Specialità in Psichiatria della Facoltà di Medicina, In Psicologia Clinica della Facoltà di Psicologia, del Master di II Livello in Psicofarmacologia Clinica della Facoltà di Medicina e Chirurgia e dei corsi di Laurea Magistrale in Medicina e Chirurgia e Psicologia e di Laurea Triennale in Scienze Psicologiche.

E’ Direttore del Master di II livello  in Psicofarmacologia Clinica dell’Università Vita Salute San Raffaele di cui era coordinatore clinico dal 2005 e membro dei comitati ordinatore e di progetto sin dall’istituzione nel 2002.

E’ autore e coautore ed editor di più di 100 pubblicazioni su riviste e libri nazionali ed internazionali e monografie su temi di clinica e neurobiologia psichiatrica, neuropsicologia clinica, riabilitazione neuropsicologica, neuropsichiatria, psicofarmacologia clinica, sorveglianza e epidemiologia degli effetti dei farmaci psicotropi e farmacocinetica. Il principale ambito di pubblicazione è quello della schizofrenia e dei disturbi psicotici ed in particolare più recentemente quello sullo sviluppo di strategie di riabilitazione neurocognitiva dei deficit cognitivi e della modulazione genetica delle prestazioni cognitive nella schizofrenia.

Ha organizzato di numerosi  convegni Nazionali ed Internazionali su temi di psicofarmacologia clinica e psichiatria. Dal  2008 è organizzatore e chairman del   ‘Cognition in schizophrenia satellite meeting’ del convegno biennale mondiale della Schizophrenia International Research Society.

E’ membro dell’Editorial Board della rivista del Gruppo Elsevier Schizophrenia Research: Cognition, ed è stato membro del Comitato di Revisione Scientifica per L’edizione Italiana del DSM V

E’ membro dell’ European College of Neuropsychopharmacology (ECNP)  e ‘Fellow ’ dell’ European College of Neuropsychopharmacology nell’ambito del ‘ECNP certificate initiative’.

 

Selection of Representative Publications

Altamura AC, Mauri MC, Cavallaro R, A.Gorni. Haloperidol metabolism and antipsychotic effect in schizophrenia.The Lancet, (1987), I, 8536:  814-15.

Cavallaro R, Smeraldi E. A rare presentation of tardive dyskinesia American Journal of Psychiatry (1992), 149, 8:1115.

Cavallaro R, Regazzetti MG, Mundo E, Brancato V, Smeraldi E.. Tardive dyskinesia outcomes:  Clinical and Pharmacological Correlates of Remission and Persistance. Neuropsychopharmacology (1993), 8 (3): 233-239.

Cavallaro R, Regazzetti MG, Covelli GP, Smeraldi E.. Tolerance and withdrawal with zolpidem. Lancet (1993), 342 (8867) 374-375.

Gambini O., Colombo C, Cavallaro R., Scarone S.. Smooth pursuit eye Movements and saccadic eye movements in patients with delusional disorder. Am J Psychiatry (1993), 150 (9):1411-1414.

Cavallaro R, Brambilla P, Smeraldi E. The sequential treatment approach to resistant schizophrenia with risperidone and clozapine: results of an open study with follow-up. Hum. Psychopharmacol Clin Exp (1998),  13 (2): 91-97.

Benedetti F, Cavallaro R, Smeraldi E.   Olanzapine induced neutropenia after clozapine induced neutropenia Lancet  (1999), 354 (9178) : 567

Cavallaro R, Mistretta P, Cocchi F, Manzato M, Smeraldi E. Differential efficacy of risperidone versus haloperidol in psychopathological subtypes of subchronic schizophrenia. Hum Psychopharmacol Clin Exp (2001), 16 (6): 439-42

Cavallaro R, Galardi G, Cavallini MC, Henin M, Amodio S, Bellodi L, Comi G. Obsessive compulsive disorder among idiopathic focal dystonia patients: An epidemiological and family study. Biological  Psychiatry (2002), 52 (4): 356-361

Lerer B, Segman RH, Fangerau H, Daly AK; Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology (2002), 27( 1): 105-119

Cavallaro R, Cavedini P, Mistretta P, Bassi T, Angelone SM, Ubbiali A, Bellodi L. Basal Corticofrontal Circuits in Schizophrenia and Obsessive-Compulsive Disorder: A Controlled Double Dissociation Study . Biological Psychiatry (2003), 54 (4):437–443

Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone induced hyperprolactinaemia: a pilot study Journal of Clinical Psychiatry. (2004), 65(2):187-90

Pieroni M, Cavallaro R, Chimenti C, Smeraldi E, Frustaci A. Clozapine induced hypersensitivity Myocarditis. Chest, (2004), 126 (5):1703-5.

 

Lerer B, Segman RH, Tan E, Basile VS, Cavallaro R, Aschauer HN,  Strous R, Chong SA, Heresco-Levy U, Verga M, Scharfetter J,  Meltzer HY, Kennedy JL, Macciardi F. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. International Journal of Neuropsychopharmacology (2005)  8(3): 411-25.

Rossi A, Daneluzzo E, Tomassini A, Struglia F, Cavallaro R, Smeraldi E, Stratta P.  The effect of verbalization strategy on Wisconsin Card Sorting Test performance in schizophrenic patients receiving classical or atypical antipsychotics. BMC Psychiatry. (2006), 6: 3.

van Os J,  Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, Bernardo M, Arango C,  Fleischhacker W, Lachaux B, Kane JM . Standardised remission criteria in schizophrenia Acta Psychiatrica Scandinavica (2006),  113 (2): 91-5.

Anselmetti S, Cavallaro R, Bechi M, Angelone SM, Ermoli E, Cocchi F, Smeraldi E Psychopathological and neuropsychological correlates of source monitoring impairment in schizophrenia. Psychiatry Research (2007), 150 (1): 51-59.

Bosia M, Bechi M, Marino E, Anselmetti S, Poletti S, Cocchi F, Smeraldi E, Cavallaro R.  Influence of Catechol-O-Methyltrasferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia . Neuroscience Letters (2007) 417 (3): 271-247

Spina E, Cavallaro R. The safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opinion on Drug Safety (2007),  6 (6):651-62. ISSN: 1474-0338

Anselmetti S, Poletti S, Ermoli E, Bechi M, Cappa S, Venneri A, Smeraldi E, Cavallaro R.  The Brief Assessment of Cognition in Schizophrenia. Normative data for the Italian population. Neurological  Sciences. (2008), 29(2):85-92

Anselmetti S, Bechi M, Bosia M, Quarticelli C, Ermoli E, Smeraldi E, Cavallaro R. ‘Theory’ of mind impairment in patients affected by schizophrenia and in their parents. Schizophrenia Research (2009),115 (2): 278-85.

Cavallaro R, Anselmetti S, Poletti S, Bechi M, Ermoli E, Cocchi F, Stratta P, Vita A, Rossi A, Smeraldi E. Computer-aided neurocognitive remediation as an enhancing strategy for schizophrenia rehabilitation. Psychiatry Research (2009), 169(3):191-6.

Benedetti F, Bernasconi A, Bosia M, Cavallaro R, Dallaspezia S, Falini A, Poletti S, Radaelli D, Riccaboni R, Scotti G, Smeraldi E. Functional and structural brain correlates of theory of mind and empathy deficits in schizophrenia. Schizophrenia Research (2009), 114 (1) :154-60.

Bosia M, Anselmetti S, Pirovano A, Ermoli E, Marino E, Bramanti P, Smeraldi E, Cavallaro R. HTTLPR functional polymorphism in schizophrenia: executive functions vs. sustained attention dissociation. Prog Neuropsychopharmacol Biol Psychiatry. (2010); 34 (1): 81-5. 49) Schettino A, Lauro LR, Crippa F,

Anselmetti S, Cavallaro R, Papagno C. The comprehension of idiomatic expressions in schizophrenic patients. Neuropsychologia. (2010), 48 (4): 1032-40.

Poletti, S., Anselmetti, S., Bechi, M., Ermoli, E., Bosia, M., Smeraldi, E., Cavallaro, R.Computer-aided neurocognitive remediation in schizophrenia: Durability of rehabilitation outcomes in a follow-up study Neuropsychological Rehabilitation (2010), 20 (5):659-674

Bosia, M., Anselmetti, S., Bechi, M., Lorenzi, C., Pirovano, A., Cocchi, F., Buonocore, M., Bramanti, P., Smeraldi, E., Cavallaro, R. Effect of 5-HT1A-receptor functional polymorphism on Theory of Mind performances in schizophrenia Psychiatry Research (2011), 188 (2): 187-90.

Rabinowitz, J., Napryeyenko, O., Burba, B., Martinez, G., Neznanov, N.G., Fischel, T., Baylé, F.J., Cavallaro, R., Smeraldi, E., Schreiner, A. Premorbid functioning and treatment response in recent-onset schizophrenia: Prospective study with risperidone long-acting injectable Journal of Clinical Psychopharmacology (2011),  31 (1): 75-81.

Spangaro M, Bosia M, Zanoletti A, Bechi M, Cocchi F, Pirovano A, Lorenzi C, Bramanti P, Benedetti F, Smeraldi E, Cavallaro R. Cognitive dysfunction and glutamate reuptake: Effect of EAAT2 polymorphism in schizophrenia. Neuroscience  Letters. (2012), 522(2):151-5.

Llorca PM, Blanc O, Samalin L, Bosia M, Cavallaro R. Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. European Psychiatry. (2012), 27 (6): 396-400

Poletti S, Anselmetti S, Riccaboni R, Bosia M, Buonocore M, Smeraldi E, Cavallaro R. Self awareness of cognitive functioning in schizophrenia: patients and their relatives. Psychiatry Research.(2012), 198(2): 207-11

Riccaboni R, Fresi F, Bosia M, Buonocore M, Leiba N, Smeraldi E, Cavallaro R. Patterns ofevidence integration in schizophrenia and delusion. Psychiatry Research. (2012), 200 (2): 108-14

Bechi M, Riccaboni R, Ali S, Fresi F, Buonocore M, Bosia M, Cocchi F, Smeraldi E, Cavallaro R. Theory of mind and emotion processing training for patients with schizophrenia: preliminary findings. Psychiatry Research (2012), 198 (3): 371-7

Bechi M, Spangaro M, Bosia M, Zanoletti A, Fresi F, Buonocore M, Cocchi F, Guglielmino C,Smeraldi E, Cavallaro R. Theory of Mind intervention for outpatients with schizophrenia. Neuropsychological  Rehabilitation. (2013), 23 (3): 383-400

Poletti S, Radaelli D, Bosia M, Buonocore M, Pirovano A, Lorenzi C, Cavallaro R, Smeraldi E, Benedetti F. Effect of glutamate transporter EAAT2 gene variants and gray matter deficits on working memory in schizophrenia. European Psychiatry. (2014), 29 (4): 219-25

Bosia M, Zanoletti A, Spangaro M, Buonocore M, Bechi M, Cocchi F, Pirovano A, Lorenzi C, Bramanti P, Smeraldi E, Cavallaro R.  Factors affecting cognitive remediation response in schizophrenia: The role of COMT gene and antipsychotic treatment.  Psychiatry Research, (2014), 217(1): 9-14

Spangaro M, Bosia M,  Zanoletti A, Bechi M, Buonocore M, Pirovano A, Lorenzi C,  Bramanti P, Smeraldi E and Cavallaro R Exploring effects of EAATs polymorphisms on cognitive functions in schizophrenia. Pharmacogenomics (2014), 15 (7): 925-32.

Pinna F, Bosia M, Cavallaro R, Carpiniello B. Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances. Schizophrenia Research: Cognition (2014), 1:187-192

Bosia M, Pigoni A, Cavallaro R. Genomics and Epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back.  Expert Opinion in Drugs Discovery (2015), 10 (2): 125-139.

Bosia M, Lorenzi C, Pirovano A, Guglielmino C, Cocchi F, Spangaro M, Bramanti P, Smeraldi E, Cavallaro R. COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine. Pharmacogenomics (2015), 16(1): 35-44

Buonocore MC, Bosia M, Riccaboni R, Bechi M, SpangaroM, Piantanida M, Cocchi F, Guglielmino C,  Bianchi L,  Smeraldi E,  Cavallaro R. Combined neurocognitive and metacognitive rehabilitation in schizophrenia: effects on bias against disconfirmatory evidence. European Psychiatry (2015), 30(5):615-21.

Bechi M, Bosia M, Spangaro M, Buonocore M, Cocchi F, Pigoni A, Piantanida M,  Guglielmino C, Bianchi L, Smeraldi E and Cavallaro R. Combined social cognitive and neurocognitive rehabilitation strategies in schizophrenia: neuropsychological and psychopathological influences on Theory of Mind improvement. Psychological Medicine (2015), 45(15): 3147-57 .

Moro A, Bambini V, Bosia M, Anselmetti S, Riccaboni R, Cappa SF, Smeraldi E,Cavallaro R. Detecting syntactic and semantic anomalies in schizophrenia. Neuropsychologia. (2015),  79 (PtA): 147-157

Bosia M, Pigoni A, Zagato L, Merlino L, Casamassima N, Lorenzi C, Pirovano A, Smeraldi E, Manunta P, Cavallaro R. ADDing a piece to the puzzle of cognition in schizophrenia. Eur J Med Genet. (2016) 59(1):26-31

Poletti S, Mazza E, Bollettini I, Falini A, Smeraldi E, Cavallaro R, Benedetti F. The COMT Val158Met polymorphism moderates the association between cognitive functions and white matter microstructure in schizophrenia. Psychiatr Genet. (2016) 26(5):193-202

Bambini V, Arcara G, Bechi M, Buonocore M, Cavallaro R, Bosia M. The communicative impairment as a core feature of schizophrenia: Frequency of pragmatic deficit, cognitive substrates, and relation with quality of life. Compr Psychiatry. (2016) 26;71:106-120

Cognitive remediation and functional improvement in schizophrenia: Is it a matter of size? Bosia M, Buonocore M, Bechi M, Spangaro M,  Pigoni A, Croci M, Cocchi F, Guglielmino C, Bianchi L, Smeraldi E, Cavallaro R. (2017) European Psychiatry, 40: 26-32